Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were just diagnosed with AML and have a certain change in a gene called CEBPA.
- You are not healthy enough for standard strong chemotherapy (for example, due to older age, heart/lung/kidney/liver problems, on ongoing infection).
- You have not received prior chemotherapy or targeted drugs for this leukemia (except hydroxyurea).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with AML that has not responded to standard treatment, particularly if they have already taken venetoclax. The goal is to see if this new combination can help control the leukemia.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial is testing a new combination of medicines (venetoclax plus other drugs, without strong chemotherapy) for people recently diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFB::MYH11 positive). It aims to see if this gentler approach works well for patients who may not tolerate intensive chemo.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.